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Aims Remote management of heart failure using implantable electronic devices (REM-HF) aimed to assess the clinical and cost-
effectiveness of remote monitoring (RM) of heart failure in patients with cardiac implanted electronic devices (CIEDs).
...................................................................................................................................................................................................
Methods
and results
Between 29 September 2011 and 31 March 2014, we randomly assigned 1650 patients with heart failure and a
CIED to active RM or usual care (UC). The active RM pathway included formalized remote follow-up protocols,
and UC was standard practice in nine recruiting centres in England. The primary endpoint in the time to event anal-
ysis was the 1st event of death from any cause or unplanned hospitalization for cardiovascular reasons. Secondary
endpoints included death from any cause, death from cardiovascular reasons, death from cardiovascular reasons
and unplanned cardiovascular hospitalization, unplanned cardiovascular hospitalization, and unplanned hospitaliza-
tion. REM-HF is registered with ISRCTN (96536028).
The mean age of the population was 70 years (range 23–98); 86% were male. Patients were followed for a median
of 2.8 years (range 0–4.3 years) completing on 31 January 2016. Patient adherence was high with a drop out of
4.3% over the course of the study. The incidence of the primary endpoint did not differ significantly between active
RM and UC groups, which occurred in 42.4 and 40.8% of patients, respectively [hazard ratio 1.01; 95% confidence
interval (CI) 0.87–1.18; P= 0.87]. There were no significant differences between the two groups with respect to
any of the secondary endpoints or the time to the primary endpoint components.
...................................................................................................................................................................................................
Conclusion Among patients with heart failure and a CIED, RM using weekly downloads and a formalized follow up approach
does not improve outcomes.
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Introduction
Despite advances in the care of heart failure patients they remain at
high risk of death and hospitalization.1–3 Studies that have investigated
a range of remote monitoring (RM) strategies, intended to help
patients avoiding hospitalization due to heart failure deterioration,
have shown mixed outcomes with little evidence of significant clinical
benefit. It is likely that the effectiveness (and cost-effectiveness) of
RM depends on the design of care pathways in which the technolo-
gies are deployed.4
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We conducted a multicentre, randomized, controlled trial, remote
management of heart failure using implantable electronic devices
(REM-HF), to determine whether management of heart failure pa-
tients in response to information gained by RM of implanted devices
would reduce the combined endpoint of death from any cause and
hospitalization for cardiovascular reasons, as compared to usual care
(UC). To make the study as relevant as possible to real-world clinical
practice and circumstances, it was conducted using devices from mul-
tiple manufacturers. The RM follow-up processes were formalized
according to the prevailing understanding of clinical practice at the
time of study inception and allied healthcare professionals were
trained in the RM process in each of the participating centres. To our
knowledge, REM-HF is the largest study, with longest follow-up, of
RM of heart failure to date.
Methods
Study design, administration, and
supervision
A description of the study design was published previously.5 In summary,
our study was a randomized, event-driven, multicentre, open label, and
parallel group clinical trial in which patients with heart failure and a cardiac
implanted electronic device (CIED) [cardiac resynchronization therapy
(CRT) with pacemaker function (CRT-P), CRT with defibrillator function
(CRT-D), or implantable cardioverter-defibrillator (ICD)] were
randomized to receive either UC or management informed by active
remote-monitoring (RM). The active RM approach is described in detail
below. In summary, it consisted of weekly data downloads from patients’
devices with simultaneous review by remote monitors who followed a
defined active follow-up approach. Usual care was existing follow-up
practice in the participating centres and care was taken that it was not
influenced by study procedures. The context of the study was the UK’s
National Health Service and nine recruiting centres.
The study protocol (which is available at http://eprints.soton.ac.uk/
398865/) was approved by the National Research Ethics Service
Committee, Yorkshire and the Humber-Sheffield, UK. The study was reg-
istered with the UK’s Clinical Research Network (10383) and ISRCTN
(96536028) and conducted in accordance with the Good Clinical
Practice guidelines and the principles of the 2002 Declaration of Helsinki.
All patients recruited to the study provided written informed consent.
The Steering Committee oversaw the execution of the trial and data
analysis according to a pre-specified statistical analysis. A Supervisory
Committee was responsible for trial governance. An independent
Endpoint Review Committee reviewed all patient events and adjudicated
them according to its charter, detailed in the statistical analysis plan. The
trial was reviewed by an independent Data and Safety Monitoring
Committee who reviewed an interim analysis for signals of harm, over-
whelming benefit, or futility, and sanctioned study continuation when 400
primary events had been adjudicated on 27 February 2015.
Inclusion and exclusion criteria and
randomization procedure
For inclusion, patients had to have symptomatic heart failure (NYHA
Class II–IV) documented at enrolment, with a CIED (ICD;CRT-D; CRT-
P) implanted according to NICE guidance or local clinical discretion at
least 6 months previously (and optimally programmed according to the
treating physician), stable and optimal medical therapy (working to NICE
Guidelines) for heart failure for 6 weeks prior to enrolment, the ability to
independently comprehend and complete quality of life questionnaires
and to give informed consent. Patients were not eligible for recruitment if
they had had any device change or lead replacement procedure within 30
days, had had an acute myocardial infarction or any cardiac surgical proce-
dure within 3 months, were unable to use the technology due to mental
or physical limitations, were aged <18 years, were pregnant, were on a
planned heart transplantation list, had a life expectancy of less than a year
due to non-cardiovascular disease, had current CIED complications (such
as wound infection, haematoma, lead fracture), or were unable to under-
stand written and spoken English.
Patients meeting these criteria, after informed consent, were
randomized 1:1 to UC or to active RM, performed centrally by
FormsVision B.V. (Abcoude, The Netherlands) via an electronic care re-
cord form management system. The randomization schedule was strati-
fied by recruiting site and device type (CRT-P; CRT-D; ICD), with
randomly permuted block sizes of either four or 6 patients.
Remote monitoring care pathway,
procedural handbook, and remote
monitoring staff
The trial investigators adopted a pragmatic approach to active RM based
on a feasibility study,5 steering committee clinical experience, and refer-
ence to the published literature. The RM attributes of CIEDs differ be-
tween manufacturers and the parameters monitored by manufacturers’
CIEDs are listed in Table 1. Remote monitoring clinical management pro-
cedures were standardized across centres and formalized in a Procedural
Handbook (Appendix II to the protocol) that guided reactions to active
RM changes (including medication changes, lifestyle advice, and onward
referral). The Procedural Handbook integrated the monitored parame-
ters into the active RM workflow. Choice of CIED was determined by
purchasing practice in participating centres.
At each of the nine study sites, one healthcare professional (nurse
practitioner or clinical physiologist experienced in heart failure manage-
ment and/or CIED follow-up) was appointed as the monitor responsible
for screening and enrolling patients, active RM, and study management.
These monitors underwent an initial 2 days intensive training in applica-
tion of the CIED’s monitoring technologies in the study protocol, the
workflows described in the Procedural Handbook (which was written by
the steering committee to optimize monitoring capabilities based on un-
derstanding of the literature, personal experience, and learnings from a
the feasibility study described in a methodology article5) and active RM
aims. There was subsequent informal refresher training at intervals during
the study.
Following patient enrolment, they instructed participants randomized
to active RM in how to perform weekly CIED downloads. They also inter-
preted the weekly downloads with particular attention to the observa-
tion of multi-parameter trends rather than single observations (including
thoracic impedance change) and in the context of patient feedback during
telephone interviews. No ‘alerts’ were programmed ‘on’ for the purpose
of heart failure management and therefore, there was no co-ordinated
heart failure care response to ‘alert’ generation. ‘Alerts’ for lead integrity
or battery depletion were allowed according to physician discretion. The
remote monitors offered lifestyle, clinical and medication change advice
to patients within the confines of the Procedural Handbook, and addi-
tional clinic visits, or recommendation to attend their general practitioner
or the emergency room. Patients in the UC group were informed of
study follow-up procedures. The remote monitor contacted these pa-
tients by telephone to make a comprehensive assessment of heart failure
events during the study follow-up period, with completion of the study
UC CRF. However, the remote monitor was instructed not to interfere
with UC patient management and to avoid any patient interactions that
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might inadvertently do so. For UC, those sites that used RM for device
checks continued that practice as to do otherwise would have interfered
with UC. At its most frequent, this was done every 6 months and without
use of a ‘protocol-driven’ response. Usual care did not include use of ac-
tive RM to manage heart failure in any form.
Data collection and management
All study data for both the active RM and UC groups were collected and
recorded by the site staff on the electronic case record form, which cap-
tured clinical events and healthcare utilization elements.
Follow-up timing
Contact was made with all patients at 3, 6, 12, and 24 months and at the
end of the study.
Continual on-site monitoring was performed with source-data verifi-
cation of core data in all patients. Central monitoring of documents (pa-
tients’ records and electronic case report forms) regarding serious
adverse events was performed before assessment by the endpoint review
committee. The trial was terminated after the protocol-specified goal of
546 identified and adjudicated primary endpoints was met, and patients
exited from the study with an end-of-trial telephone contact so that any
remaining endpoints or adverse events could be collected before the
database was locked.
End points
The primary study endpoint in the time-to-event analysis was the 1st
event of the composite of death from any cause or an unplanned hospital-
ization for cardiovascular reasons. The secondary endpoints were death
from any cause; cardiovascular death; non-cardiovascular death;
cardiovascular-related death or unplanned cardiovascular hospitalization;
death from any cause or unplanned hospitalization for non-
cardiovascular reason; unplanned cardiovascular hospitalization;
unplanned hospitalization for non-cardiovascular reasons.
Statistical analysis
The study was designed to show a maximum hazard ratio (HR) of 0.755
in the rate of the 1st primary end-point event with RM. We calculated
that data on 546 events were required for the study to have power of
90% to show that reduction, at an overall two-sided type I error rate of
5%. We estimated that this would require a minimum of 697 patients to
be recruited per group (1394 total) with a minimum follow-up of 2 years,
but to allow for patient drop-out, we increased the total planned recruit-
ment to 1650.
The primary analysis was conducted in the intention to treat popu-
lation, which consisted of all randomized subjects, with each subject
analysed as part of the group to which they were randomized and
....................................................................................................................................................................................................................
Table 1 Parameters measured by cardiac implanted electronic devices for remote monitoring and used to guide
interventions
Medtronic Boston scientific St Jude medical
Bi-ventricular pacing % Bi-ventricular pacing % Bi-ventricular pacing %
Nocturnal HR
Thoracic Impedance Thoracic impedance (if programmed on)
Activity levels Activity levels Activity levels
AT/AF burden AT/AF burden AT/AF burden
Ventricular arrhythmias Ventricular arrhythmias Ventricular arrhythmias
Therapy from device Therapy from device Therapy from device
Heart rate variability Heart rate variability (SDANN)
Lead integrity Lead integrity Lead integrity
Device programming Device programming Device programming
V–V interval at time of D/L V–V interval at time of D/L V–V interval at time of D/L
HR, hazard ratio; AT, atrial tachycardia; AF, atrial fibrillation.
1650 Patients were randomised 
824 were assigned to receive 
the Usual Care pathway 
826 were assigned to receive 
the Remote Monitoring 
807 Completed Baseline 
Assessment
810 Completed Baseline 
Assessment
5 Violated 
inclusion or 
exclusion criteria 
8 Had data censored because they 
withdrew full consent (including 
for GP follow-up) 
5 Underwent a heart transplant 
13 Violated 
inclusion or 
exclusion criteria 
674 Completed 1 year 
Assessment
5 Withdrew from 
data collection 
(GP FU 
595 Completed 2 year 
Assessment
7 Withdrew from 
data collection 
(GP FU 
669 Completed 1 year 
Assessment
34 Withdrew 
from data 
collection
596 Completed 2 year 
Assessment
16 Withdrew 
from data 
collection
2 Had data censored because they 
withdrew full consent (including for 
GP follow-up) 
3 Underwent a heart transplant 
Figure 1 Randomization, treatment, and follow-up of the pa-
tients. GP, general practitioner doctor.
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Table 2 Demographic and clinical characteristics of the patients at baseline, according to treatment groupa
Characteristic Randomized group
Remote monitoring n5 824 Usual care n5 826 Total n51650
Age (years) 69.5 ± 10.31 69.5 ± 10.04 69.5 ± 10.17
Age (years)—Females 66.5 ± 11.90 68.00 ± 11.47 67.2 ± 11.69
Age (years)—Males 69.9 ± 9.95 69.8 ± 9.76 69.9 ± 9.85
Male sex 707 (85.8%) 708 (85.7%) 1415 (85.8%)
BMI 28.9 (5.72) 28.8 (5.48) 28.9 (5.60)
BMI—Females 29.0 (6.55) 28.1 (6.34) 28.6 (6.45)
BMI—Males 28.9 (5.58) 28.9 (5.32) 28.9 (5.45)
Recruiting Site Blackpool 98 (11.9%) 102 (12.4%) 200 (12.1%)
Brompton 85 (10.3%) 84 (10.2%) 169 (10.2%)
Guys 64 (7.8%) 65 (7.9%) 129 (7.8%)
Leeds 102 (12.4%) 99 (12.0%) 201 (12.2%)
Leicester 102 (12.4%) 100 (12.1%) 202 (12.2%)
Liverpool 98 (11.9%) 105 (12.7%) 203 (12.3%)
Manchester 101 (12.3%) 99 (12.0%) 200 (12.1%)
Newcastle 95 (11.5%) 93 (11.3%) 188 (11.4%)
Southampton 79 (9.6%) 79 (9.6%) 158 (9.6%)
NYHA Classification II 585 (71.0%) 561 (67.9%) 1146 (69.5%)
III 238 (28.9%) 263 (31.8%) 501 (30.4%)
IV 1 (0.1%) 2 (0.2%) 3 (0.2%)
Myocardial infarction 497/818 (60.1%) 478/818 (58.4%) 975/1636 (59.6%)
Coronary artery bypass surgery 268/819 (32.7%) 247/818 (30.2%) 515/1637 (31.5%)
Percutaneous coronary suregery 209/819 (25.5%) 190/818 (23.2%) 399/1637 (24.4%)
Valve replacement 66/819 (8.1%) 51/819 (6.2%) 117/1638 (7.1%)
Diabetes mellitus Type I 5/819 (0.6%) 9/819 (1.1%) 14/1638 (0.9%)
Type II 203/819 (24.8%) 216/819 (26.4%) 419/1638 (25.6%)
Type II diabetics on medication 155 (76.4%) 171 (79.9%) 369 (80.2%)
Systolic blood pressure (mmHg) 118.9 ± 17.61 119.1 ± 18.43 119.0 ± 18.02
Diastolic blood pressure (mmHg) 70.1 ± 11.02 70.1 ± 11.33 70.1 ± 11.17
Type of cardiac implantable device ICD 275 (33.4%) 276 (33.4%) 551 (33.4%)
CRT-D 442 (53.6%) 438 (53.0%) 880 (53.3%)
CRT-P 107 (13.0%) 112 (13.6%) 219 (13.3%)
Pulse (beats/minute) 68.1 (10.22) 68.6 (9.92) 68.3 (10.07)
History of atrial fibrillation 339/819 (41.4%) 338/816 (41.4%) 677/1635 (41.4%)
Haemoglobin (g/L) 134.6 ± 15.57 133.1 ± 16.22 133.8 ± 15.91
Documented coronary artery disease 563/819 (68.7%) 548/818 (67.0%) 1111/1637 (67.9%)
Left ventricular ejection fraction (%) 29.9 ± 10.24 30.0 ± 9.81 29.9 ± 10.02
Smoking history Never smoked 275 (33.6%) 262 (32.0%) 537 (32.8%)
Ex-smoker 471 (57.5%) 495 (60.4%) 966 (59.0%)
Current smoker 73 (8.9%) 62 (7.6%) 135 (8.2%)
Oral anticoagulant 394 (47.8%) 389 (47.1%) 783 (47.5%)
ACE inhibitor or ARB 750 (91.0%) 754 (91.3%) 1504 (91.2%)
Beta-blocker 749 (90.9%) 746 (90.3%) 1495 (90.6%)
Aldosterone antagonist 430 (52.2%) 435 (52.7%) 865 (52.4%)
Diuretic (excluding aldosterone antagonists) 635 (77.1%) 631 (76.4%) 1266 (76.7%)
Antiplatelet 485 (58.9%) 448 (54.2%) 933 (56.5%)
Cardiac glycoside 153 (18.6%) 180 (21.8%) 333 (20.2%)
Anti-arrhythmic 205 (24.9%) 203 (24.6%) 408 (24.7%)
ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; ICD, implant-
able cardioverter defibrillator; CRT-D, cardiac resynchronization therapy with defibrillator function; CRT-P, cardiac resynchronization therapy with pacemaker function; BMI,
body mass index.
aAll comparisons between the two groups were non-significant (P> 0.05).
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..including all events that occurred before the database was locked.
This included any subjects later found to be ineligible and those who
did not follow the trial protocol. The trial was designed to include one
interim analysis and used the Peto–Haybittle rule to maintain an over-
all 5% type I error. The significance level of the final analysis was 0.048.
Cox proportional hazards models including the stratification variables
of recruiting site and device type were used to test for differences be-
tween the UC and active RM groups. The excess of events at the ter-
mination of the trial was included in the final analyses. Cause-specific
HR was calculated, and cumulative incidence curves were used to vis-
ualize survival data. Further details regarding the statistical analysis, in-
cluding analyses of the secondary endpoints and a priori subgroup
analyses, are provided in the statistical analysis plan (Appendix III to
the protocol).
Manuscript preparation
The study funders and sponsor had no role in study design, collec-
tion, analysis, and interpretation of data, manuscript preparation or
decision to submit the article for publication. The 1st draft of the
manuscript was prepared by the study principal investigators (JMM
and MRC), who, with the trial statistician, had unrestricted access to
the data. The manuscript was reviewed and edited by all the authors.
All the authors made the decision to submit the manuscript for publi-
cation and assume responsibilities for the accuracy and completeness
of the analyses and for the fidelity of this report to the trial protocol.
Results
Between 29 September 2011 and 31 March 2014 1650 patients were
enrolled and included in the intention-to-treat analysis; 824 patients
were assigned to the UC group and 826 to the RM group (Figure 1).
Vital-status verification was completed for 100% of patients. Consent
for further follow-up was withdrawn by 72 (44%) patients during the
study (mainly due to inclusion in other heart failure therapy studies).
Baseline characteristics of the patients were similar between the two
groups (Table 2). The mean age was 70 years; 86% were male. The
majority of patients were in New York Heart Association (NYHA)
Classification II (70%) or III (30%). At baseline, 91% were taking an an-
giotensin converting enzyme inhibitor or angiotensin receptor
blocker, 91% were taking a beta-blocker, and 52% an aldosterone
antagonist.
At 6 months after randomization, 476 patients in the RM group
(58% of the 824 patients randomized) had transmitted data for at
least 75% of weeks in the study (not including any periods of hospital-
ization). This had increased to 548 patients (66%) by 12 months, and
was 513 (62%) at 24 months. A total of 79 325 CIED downloads
were reviewed in the RM group, and action was taken in 599 (73%)
of patients: in 131 of these patients (22%) action was taken in re-
sponse to only one download, in a further 201 patients (34%) action
was taken in response to two–four downloads, and 267 patients
(45%) had action taken in response to five or more downloads (maxi-
mum of 38). The actions taken, and the number of patients affected,
....................................................................................................................................................................................................................
Table 3 Actions taken in response to weekly remote download of cardiac implanted electronic devices data (remote
monitoring group)
Action Taken Number of subjects impacted (Number of Incidences) {% of patients}
Phoned Patient 520 (2378) {63.0}
Mean per patient-year 1.15
Median per patient-year (LQ–UQ) 0.43 (0–1.45)
Discussed download with clinician 408 (1390) {49.4%}
Mean per patient-year 0.68
Median per patient-year (LQ–UQ) 0 (0–0.85)
Medication change by remote monitor 134 (226) {16.2}
Mean per patient-year 0.11
Median per patient-year (LQ–UQ) 0 (0–0)
Advised to contact GP or attend a clinic Mean per patient-year 345 (910) {41.8}0.45
Median per patient-year (LQ–UQ) 0 (0–0.53)
Advised to contact GP 124 (206) {15.0}
Advised to visit HF clinic 113 (198) {13.7}
Advised to attend device clinic 202 (328) {24.5}
Advised to attend cardiovascular outpatient clinic 109 (178) {21.5}
Other advice to patient 274 (632) {(33.2}
Mean per patient-year 0.30
Median per patient-year (LQ–UQ) 0 (0–0.30)
Total 599 (5536) {72.6}
Mean per patient-year 2.68
Median per patient-year (LQ–UQ) 1.03 (0–3.36)
GP, general practitioner doctor; HF, heart failure; LQ, lower quartile; UQ, upper quartile.
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..are shown in Table 3. The numbers quoted are number of partici-
pants affected. Some participants had multiple actions with a total of
5536 actions taken on 3534 occasions (multiple actions taken at
some points).
Patients were followed for a median of 2.8 years (range 0–
4.3 years). A summary of endpoint events is provided in Figure 2. No
significant difference was seen in the rate of the primary end point,
which occurred in 349 patients (42.4%) in the RM group and in 347
patients (408%) in the UC group (HR 101; 95% confidence interval
[CI] 087 to 118; P= 087). Cumulative incidence curves for the
composite primary endpoint of death from any cause and hospital-
ization for cardiovascular reasons, as well as for both components
separately, did not reveal a significant difference between the two
groups (Figure 3). No significant differences were seen between the
two groups with respect to the secondary endpoints (Figure 2).
Subgroup analyses showed that none of the baseline characteris-
tics—including age (<70 years vs. >_70 years), gender, NYHA class
(Class I or II vs. III or IV), type of device, documented history of coro-
nary artery disease, or history of atrial fibrillation, identified a group in
which management guided by RM was more effective than UC. No
adverse events were reported during the study period.
Discussion
Active RM studies for heart failure have used a wide variety of tech-
nologies and clinical care approaches.6–11 The importance and
relevance of remote device monitoring has been considered in re-
cent European Society of Cardiology guidelines.12 In its simplest
form, active RM has used telephone-based patient support. Greater
monitoring capability is afforded by devices that collect data such as
thoracic impedance, cardiac rhythm change, haemodynamics, and pa-
tient activity. Meta-analyses of small studies suggested that this type
of active RM may reduce death from heart failure and hospital-
ization.13,14 More recently, however, the telemonitoring to improve
heart failure outcomes (Tele-HF) Trial,7 the telemedical interven-
tional monitoring in heart failure (TIM-HF),8 and the Better
Effectiveness After Transition-Heart Failure (BEAT-HF) Trial9 which
tested non-implantable RM strategies against UC, demonstrated no
effect on outcomes including death or hospitalization. However,
Tele-HF and BEAT-HF only followed patients up to 6 months and re-
ported only moderate patient compliance.7,9
More sophisticated monitoring technologies reside within CIEDs,
which are implanted for therapeutic reasons. Diagnostic capabilities
intended to signal heart failure deterioration include measurement of
intrathoracic impedance, heart rate variability, nocturnal heart rate,
patient activity, and occurrence of atrial and ventricular arrhythmia.
A further design feature of CIEDs has been used of automated ‘alerts’
when monitored parameters exceed pre-determined thresholds
considered to indicate heart failure deterioration.10,15,16 Their use, to
signal heart failure status change and trigger a therapy change, has
been a key element of the care pathway design in many RM studies,
mainly based on intrathoracic impedance measurement. However,
intrathoracic impedance has poor sensitivity and specificity for such
Figure 2 Forest plot of the comparison of end point events by treatment group.
Remote management of heart failure 2357
Downloaded from https://academic.oup.com/eurheartj/article-abstract/38/30/2352/3852228
by Edward Boyle Library user
on 16 August 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
deterioration and has been shown to drive unnecessary hospital-
izations.15 In the Optimization of Heart Failure Trial, intrathoracic im-
pedance monitoring using ‘alerts’ was not superior to routine care in
avoiding death or hospitalization related to cardiovascular causes.17
In the Clinical Evaluation of Remote Notification to Reduce Time to
Clinical Decision Trial (CONNECT) hospitalizations’ duration was
reduced in those randomized to remote notification, driven chiefly
by detection of atrial tachyarrhythmia lasting longer than 12 h but
there was no reduction in the risk of hospitalizations.11
In contrast to single parameter, ‘alert-based’ monitoring
approaches observational data of a combined multiparameter
heart failure diagnostic algorithm suggested a 30-day window of
identifying patients at higher risk of hospitalization for heart fail-
ure.18,19 The Implant-based Multiparameter Telemonitoring of
Patients with Heart Failure (IN-TIME) study tested CIED monitor-
ing of tachyarrhythmia, sub-optimal biventricular pacing, increased
ventricular extrasystolic activity, and decreased patient activity
with daily data downloads sent to a single monitoring centre.20
Comparing this strategy with UC for 12 months in 664 patients
across 36 centres there was an improvement in a combined end-
point of death from any cause, NYHA Class change and patient
global self-assessment. The study demonstrated reduced mortal-
ity in the monitored group, although this effect may have been ex-
pressed principally in patients with atrial fibrillation.
Most recently, monitoring resynchronization devices and cardiac
patients (MORE-CARE) was stopped early because of slow enrol-
ment, with 865 of a planned 1720 enrolled.21 At 24 months, follow-
up in these patients enrolled within 8 weeks of an implant of a
CRT-D device, RM using an ‘alert’ for intrathoracic impedance and
atrial tachyarrhythmias, there was no difference in the primary end-
point of all-cause mortality or hospitalization for cardiovascular or
device-related reasons.
Previous studies of CIED monitoring have used a single manufac-
turer’s devices, monitoring at a single centre (IN-TIME),20 and have
been chiefly driven by ‘alerts’ (e.g. CONNECT,11 MORE-CARE21,
OPTILINK17) which may occur too late in the course of a heart fail-
ure deterioration episode to allow pre-emptive therapy, even if ap-
propriately generated.
The REM-HF study investigators endeavoured to create a RM
strategy that is useable in real-world clinical practice. Each recruiting
centre conducted RM ‘in house’ and with multiple manufacturers’
products reflecting commercial and organizational realties which do
not easily allow the practise of RM across regional or national bound-
aries or with a single manufacturer’s technology. REM-HF did not use
‘alerts’ to trigger interactions but rather review of changes in trends
over time in monitored parameters; the incidence and nature of RM
actions in REM-HF (5536 interventions in 599 patients) appears com-
parable to that in IN-TIME (1225 actions in 280 patients). We would
argue that the patients’ adherence to the RM weekly download
schedule throughout the study was as good as was pragmatically pos-
sible, generating additional contact with the majority (72.5%) of pa-
tients. In our multicentre, randomized, controlled trial in patients
with heart failure and a CIED, we found no reduction in the risk of
death from any cause or hospitalization for cardiovascular reasons
with management guided by weekly active RM, as compared to UC in
nine English hospitals. Subgroup analyses failed to identify a group for
which the intervention was effective, including those with a history of
atrial fibrillation. This was despite both the trial having a larger num-
ber of patients and considerably longer follow-up than other similar
studies, and clinically relevant patient adherence to weekly down-
loads driving many additional contacts with patients. Importantly,
Figure 3 Cumulative incidence curves for the primary end
point, death from any cause, and unplanned hospitalization for
cardiovascular reasons. The primary endpoint was a composite
of death from any cause and unplanned hospitalization for cardi-
ovascular reasons.
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.however, we did not show an increase in hospitalization for heart fail-
ure as has been the case with pre-set ‘alert’ based approaches to RM
of CIED.15
The patient population recruited to REM-HF may have been less
sick than that in IN-TIME and OPTILINK as suggested by a higher
proportion of patients with mild symptoms (NYHA Class II).
However, the mortality rates in these studies appear similar to that
found in REM-HF. More patients gave a history of atrial fibrillation at
study enrolment in REM-HF (41.4%) than in either OPTILINK
(304%)16 or IN-TIME (254%).20
In contrast to the use of diagnostic features within therapeutically-
indicated CIEDs, two monitoring-only cardiac implantable technolo-
gies have undergone clinical trial assessment.22,23 A pressure sensor
mounted on an intravascular lead and connected to an implanted
monitoring device giving continuous right ventricular pressure moni-
toring failed to achieve a significant reduction in hospitalizations.22
However, a wireless pulmonary artery haemodynamic monitor that
allows a physician to adjust medication to achieve a target pulmonary
artery pressure reported a 33% reduction in hospitalizations at
6 months compared to UC in the US healthcare system.23 It is
unclear whether the effect relates to RM and/or to the specific hae-
modynamic targeting of drug therapy but it may be that managing pa-
tients to remain within a target zone reflecting optimal physiological
status offers better outcomes.
In summary, REM-HF employed a rigorous active RM strategy, em-
ploying the monitoring capabilities of CIEDs. The strategy was rele-
vant to real-word clinical practice and not focused on single
manufacturer technology or single centre capability although it was
implemented by trained ‘remote monitors’. Nevertheless, this active
RM strategy provided no benefit over UC for patients with heart fail-
ure. Thus, this large multicentre trial with longer follow-up than pre-
vious studies does not support the routine use of management
guided by weekly routine RM using a CIED. Perhaps an effect could
be demonstrated in health care systems with less well developed UC
or in a sicker heart failure population. Furthermore, future develop-
ments in RM technologies may enhance diagnostic and interventional
capabilities but will require robust evaluation before broad clinical
adoption.
Supplementary material
Supplementary material is available at European Heart Journal online.
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